Algorae Pharmaceuticals Appoints Dr. Sarah Siggins to Scientific Advisory Board

2 min read | November 27, 2024 09:07 PM PST | By Team Kalkine Media

Algorae Pharmaceuticals Appoints Dr. Sarah Siggins to Scientific Advisory Board — Image source: © Andreyyalansky19 | Megapixl.com

AI-Driven Drug Discovery Progress

Dr. Siggins' appointment comes after Algorae's initial readout of 24 artificial intelligence-generated drug targets, developed using its AlgoraeOS drug discovery platform. These targets are focused on treating several oncology conditions with significant unmet medical needs, including breast and lung cancer, leukaemia, and glioblastoma. The targets have been reviewed for their commercial and intellectual property potential and will now progress to preclinical studies at an Australian pharmaceutical lab.

Strategic Insight for Future Development

As a new member of the scientific advisory board, Dr. Siggins will provide strategic advice on potential commercial partnerships for AI-generated drug targets and other drug candidates owned by Algorae. Algorae’s Chair, David Hainsworth, emphasized the invaluable role Dr. Siggins' unparalleled experience in pharmaceutical innovation will play as the company advances its pipeline of drug candidates.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.